作者
Marcel A Heinrich, Ahmed MRH Mostafa, Jennifer P Morton, Lukas JAC Hawinkels, Jai Prakash
发表日期
2021/7/1
来源
Advanced drug delivery reviews
卷号
174
页码范围
265-293
出版商
Elsevier
简介
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with an overall survival rate of less than 7-8%, emphasizing the need for novel effective therapeutics against PDAC. However only a fraction of therapeutics which seemed promising in the laboratory environment will eventually reach the clinic. One of the main reasons behind this low success rate is the complex tumor microenvironment (TME) of PDAC, a highly fibrotic and dense stroma surrounding tumor cells, which supports tumor progression as well as increases the resistance against the treatment. In particular, the growing understanding of the PDAC TME points out a different challenge in the development of efficient therapeutics – a lack of biologically relevant in vitro and in vivo models that resemble the complexity and heterogeneity of PDAC observed in patients. The purpose and scope of this review is to provide an …
学术搜索中的文章
MA Heinrich, AMRH Mostafa, JP Morton… - Advanced drug delivery reviews, 2021